Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors

由 Dromain, Clarisse, Pavel, Marianne E., Ruszniewski, Philippe, Langley, Alison, Massien, Christine, Baudin, Eric, Caplin, Martyn E.
發表在 BMC Cancer (2019)

Effect of Lanreotide Depot/Autogel on Urinary 5‐Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors

由 Pavel, Marianne E., Phan, Alexandria T., Wolin, Edward M., Mirakhur, Beloo, Liyanage, Nilani, Pitman Lowenthal, Susan, Fisher, George A., Vinik, Aaron I.
發表在 Oncologist (2018)

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis

由 Strosberg, Jonathan R, Yao, James C, Bajetta, Emilio, Aout, Mounir, Bakker, Bert, Hainsworth, John D, Ruszniewski, Philippe B, Van Cutsem, Eric, Öberg, Kjell, Pavel, Marianne E
發表在 Endocr Relat Cancer (2015)

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4

由 Buzzoni, Roberto, Carnaghi, Carlo, Strosberg, Jonathan, Fazio, Nicola, Singh, Simron, Herbst, Fabian, Ridolfi, Antonia, Pavel, Marianne E, Wolin, Edward M, Valle, Juan W, Oh, Do-Youn, Yao, James C, Pommier, Rodney
發表在 Onco Targets Ther (2017)

Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors

由 Grenader, Tal, Pavel, Marianne E., Ruszniewski, Philippe B., Ćwikła, Jarosław B., Phan, Alexandria T., Raderer, Markus, Sedláčková, Eva, Cadiot, Guillaume, Wolin, Edward M., Capdevila, Jaume, Wall, Lucy, Rindi, Guido, Truong Thanh, Xuan-Mai, Caplin, Martyn E.
發表在 Anticancer Drugs (2020)

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

由 Yao, James C., Shah, Manisha H., Ito, Tetsuhide, Bohas, Catherine Lombard, Wolin, Edward M., Van Cutsem, Eric, Hobday, Timothy J., Okusaka, Takuji, Capdevila, Jaume, de Vries, Elisabeth G.E., Tomassetti, Paola, Pavel, Marianne E., Hoosen, Sakina, Haas, Tomas, Lincy, Jeremie, Lebwohl, David, Öberg, Kjell
出版 2011

Everolimus for the treatment of advanced, nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

由 Yao, James C, Fazio, Nicola, Singh, Simron, Buzzoni, Roberto, Carnaghi, Carlo, Wolin, Edward, Tomasek, Jiri, Raderer, Markus, Lahner, Harald, Voi, Maurizio, Pacaud, Lida Bubuteishvili, Rouyrre, Nicolas, Sachs, Carolin, Valle, Juan W, Fave, Gianfranco Delle, Van Cutsem, Eric, Tesselaar, Margot, Shimada, Yasuhiro, Oh, Do-Youn, Strosberg, Jonathan, Kulke, Matthew H, Pavel, Marianne E
發表在 Lancet (2015)